Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma.

Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma.

Publication date: Aug 08, 2019

The American Joint Committee on Cancer (AJCC) 8th staging system introduced several revisions. To assess the impact of the 8th edition American Joint Committee on Cancer (AJCC8) staging system on subgrouping and survival, patients with melanoma from two tertiary skin cancer centres were classified according to both the 7th edition American Joint Committee on Cancer (AJCC7) and AJCC8.

A total of 1948 patients aged ≥18 years with cutaneous melanoma stage II-IV were included. The impact of sex and age on reclassification was assessed by log binomial models. The inverse probability of censoring weighting method was used to compute ROC curves from time-to-event data to assess the discriminatory ability of AJCC7 and AJCC8. Melanoma-specific survival (MSS) and overall survival (OS) were calculated, and age- and sex-adjusted MSS hazard ratios were estimated using Cox proportional hazards models.

Of all, 23.5% of patients were assigned a different subgroup when classified according to AJCC8. Owing to upshifting to stage IIIC (AJCC7 24.8% vs. AJCC8 50.8%), patient numbers of stages IIIA and IIIB decreased from 28.7% to 16.2% and 46.5% to 28.3%. The prediction accuracy for AJCC7 and AJCC8 was comparable (integrated time-dependent area under the curve [AUC] of 0.75 and 0.74, respectively). Five-year MSS of IIB and IIC AJCC8 was poor and lower than that of IIIA AJCC8 (80%, 67% and 89%, respectively). Compared to results of the International Melanoma Database and Discovery Platform, 5-year MSS was 10-15% points lower for stages IIC, IIIB and IIIC.

Upshifting affects primarily stage III subgroups, while effects in stage II are minor. Stage IIB/C (AJCC8) patients have 67-80% MSS and should be considered for adjuvant treatment, while in stage IIIA, the indication of adjuvant treatment is questionable.

Kanaki, T., Stang, A., Gutzmer, R., Zimmer, L., Chorti, E., Sucker, A., Ugurel, S., Hadaschik, E., Gr”ager, N.S., , Satzger, Schadendorf, D., and Livingstone, E. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. 23715. 2019 Eur J Cancer (119):

Concepts Keywords
Adjuvant Cancer
AJCC Medicine
AUC Health
Binomial RTT
Dependent Area Melanoma
Melanoma Clinical medicine
Proportional Hazards Models Cancer staging
ROC
Subgroup

Semantics

Type Source Name
gene UNIPROT NR4A3
gene UNIPROT CPOX
drug DRUGBANK Saquinavir
gene UNIPROT PLXNA3
disease DOID cutaneous melanoma
disease DOID skin cancer
disease MESH skin cancer
pathway BSID Melanoma
disease DOID melanoma
disease MESH melanoma
disease DOID Cancer
disease MESH Cancer
gene UNIPROT IMPACT

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *